Thyroglobulin is a poor predictor of differentiated thyroid cancer in patients who undergo surgery for thyroid nodular diseases.
Bethesda system
Differentiated thyroid cancer
Indeterminate cytology
Multinodular goiter
Thyroglobulin
Journal
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
ISSN: 1434-4726
Titre abrégé: Eur Arch Otorhinolaryngol
Pays: Germany
ID NLM: 9002937
Informations de publication
Date de publication:
Mar 2023
Mar 2023
Historique:
received:
31
08
2022
accepted:
25
09
2022
pubmed:
8
10
2022
medline:
8
2
2023
entrez:
7
10
2022
Statut:
ppublish
Résumé
Thyroglobulin, produced exclusively by thyroid follicular cells, serves as a specific tumor marker for the follow-up of differentiated thyroid cancer (DTC) patients after thyroidectomy. However, its role as a predictor of malignancy in patients with thyroid nodules is controversial. We assessed the potential role of preoperative serum thyroglobulin concentration to predict DTC in patients without a preoperative diagnosis of malignancy who underwent partial or total thyroidectomy. This retrospective study included patients with a preoperative diagnosis of benign multinodular goiter (MNG) or a thyroid nodule with indeterminate cytology (INC) (Bethesda system categories III/IV) who underwent partial or total thyroidectomy between January 2014 and May 2019. We compared the patients' demographic, clinical, imaging, and biochemical data according to their final diagnosis: DTC or benign thyroid nodular disease. Further statistical analysis included odds ratio calculation and receiver operating characteristic (ROC) curve analysis. Of 131 patients who met inclusion and exclusion criteria, the indication for surgery was benign MNG in 69 patients and a thyroid nodule with INC in 62 patients. A final diagnosis of DTC was reported in 18 of the 69 benign MNG patients (26%) and in 30 of the 62 thyroid nodule with INC patients (48%). The preoperative measurements of nodule diameter and serum thyroid-stimulating hormone and thyroglobulin concentrations did not significantly differ between patients with a final diagnosis of DTC and those with benign histology. Preoperative serum thyroglobulin alone is insufficient to differentiate between malignant and benign thyroid nodular disease.
Identifiants
pubmed: 36205785
doi: 10.1007/s00405-022-07678-z
pii: 10.1007/s00405-022-07678-z
doi:
Substances chimiques
Thyroglobulin
9010-34-8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1311-1319Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Meltzer CJ, Irish J, Angelos P, Busaidy NL, Davies L, Dwojak S et al (2019) American Head and Neck Society Endocrine Section clinical consensus statement: North American quality statements and evidence-based multidisciplinary workflow algorithms for the evaluation and management of thyroid nodules. Head Neck [Internet] 41(4):843–856. https://doi.org/10.1002/hed.25526 (cited 2019 Jun 9)
doi: 10.1002/hed.25526
Dean DS, Gharib H (2008) Epidemiology of thyroid nodules. Best Pract Res Clin Endocrinol Metab [Internet] 22(6):901–911. https://doi.org/10.1016/j.beem.2008.09.019
doi: 10.1016/j.beem.2008.09.019
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L (2016) 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26(1):1–133. https://doi.org/10.1089/thy.2015.0020 (PMID: 26462967; PMCID: PMC4739132)
doi: 10.1089/thy.2015.0020
Durante C, Grani G, Lamartina L, Filetti S, Mandel SJ, Cooper DS (2018) The diagnosis and management of thyroid nodules: a review. JAMA [Internet] [cited 2022 Apr 9] 319(9):914–924. https://jamanetwork.com/journals/jama/fullarticle/2673975
Wu H, Swadley M (2015) The Bethesda system for reporting thyroid cytopathology: into the clinic. Pathol Lab Med Int [Internet] [cited 2019 May 24] 7:47. http://www.dovepress.com/the-bethesda-system-for-reporting-thyroid-cytopathology-into-the-clini-peer-reviewed-article-PLMI
Cibas ES, Ali SZ (2017) The 2017 Bethesda System for Reporting Thyroid Cytopathology. Thyroid 27(11):1341–1346
doi: 10.1089/thy.2017.0500
Indrasena BSH (2017) Use of thyroglobulin as a tumour marker. World J Biol Chem 8(1):81
doi: 10.4331/wjbc.v8.i1.81
Trimboli P, Treglia G, Giovanella L (2014) Preoperative measurement of serum thyroglobulin to predict malignancy in thyroid nodules: a systematic review. Horm Metab Res [Internet]. 47(04):247–252. https://doi.org/10.1055/s-0034-1395517 (cited 2019 Mar 12)
doi: 10.1055/s-0034-1395517
Jo K, Lim DJ (2018) Clinical implications of anti-thyroglobulin antibody measurement before surgery in thyroid cancer. Korean J Intern Med 33(6):1050–1057
doi: 10.3904/kjim.2018.289
Lee EK, Chung K-W, Min HS, Kim TS, Kim TH, Ryu JS, et al (2012) Preoperative serum thyroglobulin as a useful predictive marker to differentiate follicular thyroid cancer from benign nodules in indeterminate nodules. J Korean Med Sci [Internet] [cited 2019 Feb 26] 27(9):1014–8. http://www.ncbi.nlm.nih.gov/pubmed/22969246
Hulikal N, Azhagamuthu RE, Banoth M, Chowhan AK, Yutla M, Sachan A (2020) Can preoperative serum thyroglobulin levels predict the risk of malignancy? Results from prospective analysis of biochemical predictors of malignancy in thyroid nodules. Acta Otorhinolaryngol Ital 40(1):33–37
doi: 10.14639/0392-100X-N0276
Petric R, Besic H, Besic N (2014) Preoperative serum thyroglobulin concentration as a predictive factor of malignancy in small follicular and Hürthle cell neoplasms of the thyroid gland. World J Surg Oncol 12(1):1–7
doi: 10.1186/1477-7819-12-282
Petric R, Perhavec A, Gazic B, Besic N (2012) Preoperative serum thyroglobulin concentration is an independent predictive factor of malignancy in follicular neoplasms of the thyroid gland. J Surg Oncol 105(4):351–356
doi: 10.1002/jso.22030
Kars A, Aktan B, Kilic K, Sakat MS, Gözeler MS, Yörük Ö, et al (2018) Preoperative serum thyroglobulin level as a useful predictive marker to differentiate thyroid cancer. ORL J Otorhinolaryngol Relat Spec [Internet] [cited 2022 Aug 15] 80(5–6):290–295. https://pubmed.ncbi.nlm.nih.gov/30253396/
Wang L, Li H, Yang Z, Guo Z, Zhang Q (2015) Preoperative serum thyrotropin to thyroglobulin ratio is effective for thyroid nodule evaluation in euthyroid patients. Otolaryngol Head Neck Surg [Internet] [cited 2022 Aug 15];153(1):15–19. https://pubmed.ncbi.nlm.nih.gov/25883100/
Suh I, Vriens MR, Guerrero MA, Griffin A, Shen WT, Duh Q-Y, et al (2010) Serum thyroglobulin is a poor diagnostic biomarker of malignancy in follicular and Ḧurthle-cell neoplasms of the thyroid. Am J Surg [Internet] [cited 2019 Mar 21]; 200(1):41–46. https://linkinghub.elsevier.com/retrieve/pii/S0002961009007107
Kihara M, Ito Y, Hirokawa M, Masuoka H, Yabuta T, Tomoda C, et al (2011) Role of ultrasonography in patients with cytologically follicular thyroid tumor. Auris Nasus Larynx [Internet] [cited 2019 May 24] 38(4):508–11. http://www.ncbi.nlm.nih.gov/pubmed/21269788
Ahn HS, Kim HJ, Gilbert Welch H (2014) Korea’s thyroid-cancer “Epidemic”—screening and overdiagnosis. N Engl J Med 371(19):1763–1765
doi: 10.1056/NEJMp1409841
Miranda-Filho A, Lortet-Tieulent J, Bray F, Cao B, Franceschi S, Vaccarella S, et al (2021) Thyroid cancer incidence trends by histology in 25 countries: a population-based study. Lancet Diabetes Endocrinol [Internet] [cited 2021 Dec 23] 9(4):225–34. http://www.thelancet.com/article/S2213858721000279/fulltext
Mlinarić A, Horvat M, Šupak Smolčić V (2017) Dealing with the positive publication bias: Why you should really publish your negative results. Biochem Med [Internet] [cited 2022 Apr 9] 27(3):030201. https://pubmed.ncbi.nlm.nih.gov/29180912/